文献速递胸部肿瘤

利用细针穿刺标本离心上清液进行肺癌液体活检检测

Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
PubMed 文献 · Ann Oncol · 2019-01-01

研究评估肺癌细针穿刺(FNA)标本离心上清液用于检测临床相关突变的价值,共分析150例上清液样本,并采用二代测序(NGS)和微滴数字PCR(ddPCR)检测。82%样本检出体细胞突变,50%患者鉴定出符合靶向治疗或临床试验条件的临床相关突变;上清液与组织样本突变谱总体一致性高,与同期FNA和CNB分别达100%和96%,与血浆样本可操作驱动突变一致性为84%。结论认为FNA上清液可为肺癌基因分型提供有价值的标本来源,尤其适用于肿瘤组织不足的患者。

要点

  • 150例肺癌FNA上清液均获得足量DNA,116例选中样本中104例(90%)NGS成功。
  • 82%样本检出体细胞突变,50%患者发现符合靶向治疗或临床试验的临床相关突变。
  • 上清液与同期FNA和CNB突变谱一致性分别为100%和96%,与血浆可操作驱动突变一致性84%。

核心结论

  • FNA上清液可为肺癌基因分型提供有价值的标本来源,尤其适用于肿瘤组织不足的患者,从而降低多基因突变检测失败率、缩短周转时间并避免重复活检。

研究设计与样本

  • 研究评估肺癌FNA样本离心上清液(n=150)用于检测临床相关突变,并采用NGS和超敏ddPCR进行分析。
  • 部分样本的突变谱与同一患者配对组织样本(n=67)及可用的血浆液体活检检测(n=45)结果进行比较。

主要发现

  • 全部150例样本均获得足量DNA,116例选中样本中104例(90%)成功完成NGS。
  • 82%的样本检出体细胞突变,其中50%的患者鉴定出符合靶向治疗或临床试验条件的临床相关突变。
  • 上清液与对应组织样本突变谱总体一致性高,与同期FNA样本一致性为100%,与同期CNB样本一致性为96%。
  • 上清液与血浆样本可操作驱动突变比较的一致性为84%。

临床怎么用

  • 作者认为FNA上清液可为肺癌基因分型提供有价值的标本来源,尤其适用于肿瘤组织不足的患者,从而降低多基因突变检测失败率、缩短周转时间并避免重复活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tumor mutation profiling is standard-of-care in lung carcinoma patients. However, comprehensive molecular profiling of small specimens, including core needle biopsy (CNB) and fine-needle aspiration (FNA) specimens, may often be inadequate due to limited tissue. Centrifuged FNA supernatants, which are typically discarded, have emerged recently as a novel liquid-based biopsy for molecular testing. In this study, we evaluate the use of lung carcinoma FNA supernatants for detecting clinically relevant mutations. METHODS: Supernatants from lung carcinoma FNA samples (n = 150) were evaluated. Samples were further analyzed using next-generation sequencing (NGS) and ultrasensitive droplet digital PCR (ddPCR). Mutation profiles in a subset of samples were compared with results derived from paired tissue samples from the same patient (n = 67) and available plasma liquid biopsy assay (n = 45). RESULTS: All 150 samples yielded adequate DNA and NGS were carried out successfully on 104 (90%) of 116 selected samples. Somatic mutations were detected in 82% of the samples and in 50% of these patients a clinically relevant mutation was identified that would qualify them for targeted therapy or a clinical trial. There was high overall concordance between the mutation profiles of supernatants and the corresponding tissue samples, with 100% concordance with concurrent FNA and 96% with concurrent CNB samples. Comparison of actionable driver mutations detected in supernatant versus plasma samples showed 84% concordance. CONCLUSIONS: FNA supernatants can provide a valuable specimen source for genotyping lung carcinoma especially in patients with insufficient tumor tissue, thereby reducing multigene mutation profiling failure rates, improving turnaround times, and avoiding repeat biopsies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hannigan B, Ye W, Mehrotra M, et al. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens. Ann Oncol. 2019. PMID: 30887015. doi:10.1093/annonc/mdz102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。